Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.261NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.3.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.3.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EP.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EP.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.4 (Gamma)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.420NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.420NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.2.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.39.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.39.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EK.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.233NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.233NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.215NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.215NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.20NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.82NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.82NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.462NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.462NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.218NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.218NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.462NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.462NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.147NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.147NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.6 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.6 (Gamma)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.5 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.5 (Gamma)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
P.1.4 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XSNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XSNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.4.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.38NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.40NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.160.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used